alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 23.2

# Consent of Independent Auditors

We consent to the incorporation by reference in the Registration  Statements (Form F-3 No. 333-47842 and No.  333-92493),  of our report dated March 11, 2003, with respect
to the consolidated financial statements and schedules of Nur Macroprinters Ltd. included in this Annual Report (Form 20-F) for the year ended December 31, 2002.

Tel-Aviv, Israel May14,
2003

| | Yours truly,
/S/ Kost Forer & Gabbay
KOST FORER & GABBAY
A Member of Ernst & Young Global
| | -----------------------------------------------------------------------------------------



---

---
**EXHIBIT 32.2**





**CERTIFICATION
      OF PRINCIPAL FINANCIAL OFFICER**





Pursuant
      to Section 906 of the Sarbanes-Oxley Act of 2002




I,
      Andrew
      R. Skobe, Chief Financial Officer (Principal Financial Officer) of Icahn
      Enterprises G.P. Inc., the General Partner of Icahn Enterprises L.P. (the
“Registrant”), certify that, to the best of my knowledge, based upon a review of
      the Icahn Enterprises L.P., quarterly report on Form 10-Q for the period
      ended March 31, 2008 of the Registrant (the “Report”):




(1) The
      Report fully complies with the requirements of Section 13(a) or 15(d) of
      the Securities Exchange Act of 1934, as amended; and




(2) The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the
      Registrant.




/s/
                Andrew R. SkobeAndrew
                R. SkobePrincipal
                Financial Officer of Icahn Enterprises G.P. Inc., the General Partner
                of
                Icahn Enterprises L.P.


Date:
      May
      12, 2008
Exhibit
32.2
 
 
 CERTIFICATION
PURSUANT TO
 18
U.S.C. SECTION 1350,
 AS
ADOPTED PURSUANT TO
 SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 In
connection with the Annual Report of Astea International Inc. (the “Company”) on
Form 10-K for the period ending December 31, 2007 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, Rick Etskovitz,
Chief Financial Officer and Principal Financial and Chief Accounting Officer of
the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906
of the Sarbanes-Oxley Act of 2002, that:
 
 
 (3)
              The
      Report fully complies with the requirements of section 13(a) or 15(d) of
      the Securities Exchange Act of 1934;
and
 
 
 (4)
              The
      information contained in the Report fairly presents, in all material
      respects, the financial condition and results of operations of the
      Company.
 
 
 
 
 
 
 /s/Rick
      EtskovitzRick
      EtskovitzChief
      Financial Officer(Principal
      Financial and AccountingOfficer)May
      14, 2008
[No. 20552-1-II.

Division Two.

December 5, 1997.]

#### The State of Washington, *Respondent,*v. Duane Cooper, *Appellant.*

Appeal from a judgment of the Superior Court for Mason County, No. 96-1-00003-5, Toni A. Sheldon, J., entered April 4, 1996. *Affirmed*by unpublished opinion per Morgan, J., concurred in by Seinfeld and Armstrong, JJ.
38839.

#### WILKINSON v. CLARK.

Decided May 24, 1961.

*742
      *W. George Thomas,*for plaintiff in error.

Mrs. L. C. Clarke, *pro se,*contra.

Jordan, Judge.

We must agree with the trial court in dismissing the contempt for the reason stated in its order. *Code Ann.*§ 38-1201, as amended by Ga. L. 1959, pp. 425, 443, reads as follows: “In accordance with the provisions of Chapter 38-21; discovery may be had from the opposite party, either nominal or real, in any case pending in any court. Discovery may also be had from defendants in fi. fa. as to the property from which executions may be satisfied in the same manner as if said action was pending in the court to which such executions are returnable.” Clearly under the language of this Code section, discovery can only be had under its provisions from defendants in fi. fa. after conclusion of the action, and this relating only to property from which an execution might be satisfied.

This is made clearer by examination of the title to the act of the General Assembly of 1955 amending this section which reads as follows:

“An Act to amend Section 38-1201 of the Code of Georgia of 1933 relating to discovery at law, by adding to said section a provision providing that discovery at law may be had from *defendants in fi. fa.*as to the property from which executions may be satisfied; to repeal conflicting laws; and for other purposes.” Ga. L. 1955, p. 577. (Italics ours).

The plaintiff in error contends that the use of the language “as if said action was pending” in *Code*§ 38-1201, when construed with *Code Ann.*§ 38-2101 (a) dealing with depositions pending action, gives him the right to take the testimony of some peison other than a defendant in fi. fa. We think this language applies only to the manner in which the deposition of the defendants in fi. fa. must be taken and does not have the effect of broadening this section to include persons other than defendants, in fi. fa. in actions which have been completed.

Mrs. L. C. Clark, not being a defendant in fi. fa., was not required to give her deposition under the provisions of this Code section in the instant case and the court did not err in dismissing the contempt rule against her.

*Judgment affirmed.*

*Townsend, P. J., and Frankum, J., concur.*
##### 



EXHIBIT 21
  Subsidiaries
    of Oakley, Inc.
  State or Other JurisdictionSubsidiary

of Incorporation or OrganizationBarter Optical, Inc.

WashingtonBazooka, Inc.

WashingtonDragon Optical, Inc.

CaliforniaEye Safety Systems, Inc.

DelawareIacon, Inc.

TexasOakley Direct, Inc.

WashingtonOakley EDC, Inc.

WashingtonOakley Financing, Inc.

WashingtonOakley O Store, Inc.

WashingtonOakley Sales Corp.

WashingtonOliver Peoples, Inc.

CaliforniaOptical Shop of Aspen Holding

CaliforniaThe Optical Shop of Aspen,
    Inc.

CaliforniaDragon Optical Australia Pty.
    Ltd.

AustraliaOakley South Pacific Pty.
    Ltd.

AustraliaOakley Brazil Ltda.

BrazilOakley Canada, Inc.

CanadaOakley Canada Retail ULC

CanadaOakley Limited Partnership

CanadaOakley Costa Rica S.A.

Costa RicaOakley Denmark ApS

DenmarkOakley Holding S.A.S.

FranceOakley Europe SNC

FranceOakley GmbH

GermanyOliver Peoples GmbH

GermanyOakley Guatemala S.A.

GuatemalaOakley Italy Srl.

ItalyOakley Ireland Optical Limited

IrelandOakley Japan KK

JapanOakley Mexico Inc., S.A. de
    C.V.

MexicoOakley Athletic (Proprietary)
    Ltd.

South AfricaOakley Africa Eyewear Pty.
    Ltd.

South AfricaOakley (Schweiz) GmbH

SwitzerlandOakley U.K. Ltd.

United Kingdom
Editorial Note on Part 179
Editorial Note: Nomenclature changes to part 179 appear at 70 FR 72074, Dec. 1, 2005.

§ 179.41 Pulsed light for the treatment of food. Pulsed light may be safely used for treatment of foods under the following conditions: ( a ) The radiation sources consist of xenon flashlamps designed to emit broadband radiation consisting of wavelengths covering the range of 200 to 1,100 nanometers (nm), and operated so that the pulse duration is no longer than 2 milliseconds (msec);
( b ) The treatment is used for surface microorganism control;
( c ) Foods treated with pulsed light shall receive the minimum treatment reasonably required to accomplish the intended technical effect; and
( d ) The total cumulative treatment shall not exceed 12.0 Joules/square centimeter (J/cm2.)
[61 FR 42383, Aug. 15, 1996]
#### Dugan *v.*Dugan.

[No. 17,332.

Filed January 30, 1945.]

*C. James McLemore,*of Indianapolis, for appellant.

*Russell J. Deam*and *Robert L. Carrico,*of Indianapolis, for appellee.

Hamilton, J.

— The only error relied upon for reversal in this case is the overruling of appellant’s motion for a new trial. Assigned reasons for a new trial are two and read as follows:

> “1. That each and all of said rulings and decrees of this Court are contrary to the law.

> “2. And that each and all of said rulings and decrees of this Court are contrary to the evidence.”

Our statute, § 2-2401, Burns’ 1933, § 368 Baldwin’s 1934, prescribes eight grounds for new trial, none of which, and particularly the sixth, is assigned in appellant’s motion.

*330It has frequently been held by both the Supreme and Appellate Courts that specifications of error in a motion for new trial not prescribed by the statute present no question for consideration upon appeal. *Board of Commissioners of Lake County*v. *Hayhurst*(1936), 209 Ind. 416, 199 N. E. 258; *Seisler*v. *Smith*(1898), 150 Ind. 88, 46 N. E. 993; *Zimmerman*v. *Zumpfe*(1941), 218 Ind. 476, 33 N. E. (2d) 102; *Bass*v. *Citizens Trust Co.*(1904), 32 Ind. App. 583, 70 N. E. 400; *Seymour*v. *Seymour*(1941), 110 Ind. App. 75, 37 N. E. (2d) 269; *Camack*v. *Kentucky Home Mut. Life Ins. Co.*(1943), 113 Ind. App. 538, 49 N. E. (2d) 384.

No questions having been properly presented' and assigned in this appeal, the judgment must be affirmed. Judgment affirmed.

Note. — Reported in 58 N. E. (2d) 936.
<TABLE> <S> <C>

<ARTICLE> 9
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                           6,586
<INT-BEARING-DEPOSITS>                               0
<FED-FUNDS-SOLD>                                     0
<TRADING-ASSETS>                                     0
<INVESTMENTS-HELD-FOR-SALE>                    281,217
<INVESTMENTS-CARRYING>                               0
<INVESTMENTS-MARKET>                                 0
<LOANS>                                        328,083
<ALLOWANCE>                                      2,613
<TOTAL-ASSETS>                                 636,042
<DEPOSITS>                                     457,056
<SHORT-TERM>                                   107,200
<LIABILITIES-OTHER>                              4,851
<LONG-TERM>                                          0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                      66,935
<TOTAL-LIABILITIES-AND-EQUITY>                 636,042
<INTEREST-LOAN>                                 21,206
<INTEREST-INVEST>                               23,605
<INTEREST-OTHER>                                   467
<INTEREST-TOTAL>                                45,278
<INTEREST-DEPOSIT>                              16,827
<INTEREST-EXPENSE>                              23,656
<INTEREST-INCOME-NET>                           21,622
<LOAN-LOSSES>                                      500
<SECURITIES-GAINS>                             (1,093)
<EXPENSE-OTHER>                                 18,443
<INCOME-PRETAX>                                  3,968
<INCOME-PRE-EXTRAORDINARY>                       3,172
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,172
<EPS-PRIMARY>                                      .68
<EPS-DILUTED>                                      .68
<YIELD-ACTUAL>                                    3.45
<LOANS-NON>                                      2,334
<LOANS-PAST>                                       404
<LOANS-TROUBLED>                                     0
<LOANS-PROBLEM>                                  2,194
<ALLOWANCE-OPEN>                                 3,241
<CHARGE-OFFS>                                    1,140
<RECOVERIES>                                        12
<ALLOWANCE-CLOSE>                                2,613
<ALLOWANCE-DOMESTIC>                             2,613
<ALLOWANCE-FOREIGN>                                  0
<ALLOWANCE-UNALLOCATED>                              0
        

</TABLE>
§ 225.20 Buildings. ( a ) The location, design, construction, and physical size of the buildings and other production facilities are factors important to the manufacture of medicated feed. The features of facilities necessary for the proper manufacture of medicated feed include provision for ease of access to structures and equipment in need of routine maintenance; ease of cleaning of equipment and work areas; facilities to promote personnel hygiene; structural conditions for control and prevention of vermin and pest infestation; adequate space for the orderly receipt and storage of drugs and feed ingredients and the controlled flow of these materials through the processing and manufacturing operations; and the equipment for the accurate packaging and delivery of a medicated feed of specified labeling and composition.
( b ) The construction and maintenance of buildings in which medicated feeds are manufactured, processed, packaged, labeled, or held shall conform to the following: ( 1 ) The building grounds shall be adequately drained and routinely maintained so that they are reasonably free from litter, waste, refuse, uncut weeds or grass, standing water, and improperly stored equipment.
( 2 ) The building(s) shall be maintained in a reasonably clean and orderly manner.
( 3 ) The building(s) shall be of suitable construction to minimize access by rodents, birds, insects, and other pests.
( 4 ) The buildings shall provide adequate space and lighting for the proper performance of the following medicated feed manufacturing operations: ( i ) The receipt, control, and storage of components.
( ii ) Component processing.
( iii ) Medicated feed manufacturing.
( iv ) Packaging and labeling.
( v ) Storage of containers, packaging materials, labeling and finished products.
( vi ) Routine maintenance of equipment.
#### § 520.2123 Spectinomycin oral dosage forms.
Exhibit 23 (a)
Consent of Independent Auditors

We consent to the incorporation by reference in the Registration Statements
on Form S-8 pertaining to the 1998 Non-Employee Director Stock Option Plan,
the 1992 Non-Employee Director Stock Option Plan and 1992 Stock Option Plan
of Concepts Direct, Inc. of our report dated February 25, 2000, with respect
to the financial statements and schedule II of Concepts Direct, Inc.
included in its Annual Report (Form 10-K) for the year ended December 31,
1999.

/s/ Ernst & Young
Denver, Colorado
March 30, 2000
###### Editorial Note on Part 184

#### Editorial Note:

Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

#### § 184.1121 Red algae.

(a) Red algae are seaweeds of the species *Gloiopeltis furcata, Porphyra crispata, Porphyra deutata, Porphyra perforata, Porphyra suborbiculata, Porphyra tenera* and *Rhodymenia palmata. Porphyra* and *Rhodymenia* are harvested principally along the coasts of Japan, Korea, China, Taiwan, and the East and West coasts of the United States. *Gloiopeltis* is harvested principally in southern Pacific coastal waters. The material is dried and ground or chopped for use in food.

(b) The ingredient meets the specifications for kelp in the Food Chemicals Codex, 3d Ed. (1981), p. 157, which is incorporated by reference, except that the loss on drying is not more than 20 percent and the maximum allowable level for iodine is 0.05 percent. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html.*

(c) In accordance with § 184.1(b)(2), the ingredient is used in food only within the following specific limitations:

| Category of food | Maximum level of use in food (as served) | Functional use |
| --- | --- | --- |
| Spices, seasonings, and flavorings, § 170.3(n)(26) of this chapter | Not to exceed current good manufacturing practice | Flavor enhancer, § 170.3(o)(11) of this chapter; flavor adjuvant, § 170.3(o)(12) of this chapter. |

(d) Prior sanctions for this ingredient different from the use established in this section do not exist or have been waived.

[47 FR 47376, Oct. 26, 1982]
<PAGE>   1
                                                               Exhibit 16.1



March 30, 1998


Office of the Chief Accountant
Securities and Exchange Commission
450 5th Street N.W.
Washington D.C. 20549


Gentlemen,

We have been furnished with a copy of the response to Item 8 of Form 10-KSB for
the event that occured on March 26, 1998, to be filed by our former client,
Data Dimensions, Inc. We agree with the statements made in response to that
Item insofar as they relate to our Firm.

Very truly yours,


/s/ BDO Seidman, LLP
BDO Seidman, LLP

cc:
Data Dimensions
Exhibit








Exhibit 10.5
Amendment 1
to the Edwards Lifesciences Corporation
Severance Plan


Pursuant to Article VI of the Edwards Lifesciences Corporation Severance Plan (the “Plan”), the Corporate Vice President of Human Resources hereby amends the Plan effective January 1, 2017 as follows:


		
	1.
	Article II, Section (e) is amended to read as follows




“‘Eligible Employee’ means each Employee who is a regular employee (not a temporary employee) who is employed by an Employer and is scheduled to work at least twenty (20) hours each week, and is on a U.S. payroll of an Employer.  Notwithstanding the foregoing, the term “Eligible Employee” shall exclude:  (1) any individual who performs services for an Employer pursuant to an agreement (written or oral) that classifies such individual as an independent contractor or as an employee of another entity, or that otherwise contains a waiver of participation in this Plan, regardless of such individual’s employment status under common law, (2) any individual who is considered a “leased employee” as defined in Section 414(n)(2) of the Code who is employed by another entity, (3) individuals classified as Inpatriate Employees, (4) any individual whose terms of employment are governed by a collective bargaining agreement (unless the bargaining agreement provides for participation in the Plan) (5) any employee who refuses to accept another position within the Company or with a successor employer, (6) any employee whose job is outsourced to an employer who is not a member of the controlled group; provided such employee is offered a position with such employer, regardless of the terms and conditions of such offer, (7) sunset employees (employees who are hired for a specific period of time), (8) employees who fail to timely sign a general release agreement provide by the Employer; (9) employees who fail to return from a leave of absence in a timely manner (including but not limited to those employees who are on medical or disability leave and fail to return to work in a timely manner after they have been determined to no longer be disabled), and (10) any employee classified as an intern.”


EDWARDS LIFESCIENCES CORPORATION


By:  /s/  Christine Z. McCauley


Name: Christine Z. McCauley


Title: Chairperson, Administrative and Investment Committee


Date:  February 24, 2017
- All
            - Title
            - Author
            - Subject
            - Date
            - Full-Text

            -                              Explore                            ******                - Educational Resources
              - Archival Collections
              -                                      Themes                                    ******                  - Economic Data
                - Federal Reserve
                - View all 
              - Timelines 
            -                              Browse                            ******                - Titles
              - Authors
              - Subjects
              - Dates 
            -                              About                            ******                - About FRASER
              - FAQ
              - Contact Us
              -                                      FRASER API                                    ******                  - REST API
                - OAI-PMH 
            - Inside FRASER Blog

            - **

Home                 > Browse by Title > Series of Studies on Employment of Women in Various Defense Industries

              																								United States. Women's Bureau.						"Women's Wartime Jobs in Cane-Sugar Refineries : Women's Bureau Bulletin, No. 192-9" in *Series of Studies on Employment of Women in Various Defense Industries : Women's Bureau Bulletin, No. 192*			(1945).						https://fraser.stlouisfed.org/title/5465/item/539661, accessed on September 25, 2024.	    

        - **FRASER**
        - About
        - FAQ
        - Legal and Privacy
        - FRASER API

          -                              @FedFRASER 
          - ** Contact Us
          -  **  What's New  
          -  **  Inside FRASER
§ 524.1443 Miconazole. ( a ) *Specifications.* ( 1 ) Each gram of cream contains miconazole nitrate equivalent to 20 milligrams miconazole base.
( 2 ) Each gram of lotion or spray contains miconazole nitrate equivalent to 1 percent miconazole base.
( b ) *Sponsors.* See § 510.600(c) of this chapter for use as in paragraph (c) of this section: ( 1 ) No. 000061 for use of cream, lotion, and spray;
( 2 ) Nos. 054925 and 058829 for use of lotion and spray.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Apply once daily by rubbing into or spraying a light covering on the infected site and the immediate surrounding vicinity. Continue treatment for 2 to 4 weeks until infection is completely eradicated as determined by appropriate laboratory examination.
( 2 ) *Indications for use.* For topical treatment of infections caused by *Microsporum canis*, *Microsporum gypseum*, and *Trichophyton mentagrophytes.*
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[71 FR 13542, Mar. 16, 2006]
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.54 Emergency research under § 50.24 of this chapter. ( a ) The sponsor shall monitor the progress of all investigations involving an exception from informed consent under § 50.24 of this chapter. When the sponsor receives from the IRB information concerning the public disclosures required by § 50.24(a)(7)(ii) and (a)(7)(iii) of this chapter, the sponsor promptly shall submit to the IND file and to Docket Number 95S-0158 in the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, copies of the information that was disclosed, identified by the IND number.
( b ) The sponsor also shall monitor such investigations to identify when an IRB determines that it cannot approve the research because it does not meet the criteria in the exception in § 50.24(a) of this chapter or because of other relevant ethical concerns. The sponsor promptly shall provide this information in writing to FDA, investigators who are asked to participate in this or a substantially equivalent clinical investigation, and other IRB's that are asked to review this or a substantially equivalent investigation.
[61 FR 51530, Oct. 2, 1996, as amended at 68 FR 24879, May 9, 2003; 88 FR 45065, July 14, 2023]